The global lung cancer therapeutics market size attained a value of USD 28.6 billion in 2023. The market is likely to grow at a CAGR of 11.60% during the forecast period of 2024-2032 to attain a value of USD 76.9 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Cancer refers to multiple tumours that can start developing in one of the body parts and spread uncontrollably to other parts of the body. Tumours are lumps of tissue which are often identified as the initial symptoms of cancer. In the later stages, when the cancerous cells spread abnormally to other organs, it becomes extremely difficult to treat them. This process is known as metastasis.
One of the primary causes of lung cancer is smoking. It can also happen due to using other types of tobacco and inhaling secondhand smoke or due to genetic factors.
The number of people smoking and adopting unhealthy lifestyles has become one of the major factors for the rising prevalence of lung cancer patients.
The development of advanced targeted treatments such as chemotherapy and radiation therapy. Moreover, with the FDA approving immunotherapy for lung cancer treatment, the market is likely to witness further growth in the forecast period.
Companies have started to invest in research and development teams and collaborate with institutes to study and develop innovative treatment methods. This can further bolster the market growth in the coming years.
Governments of different countries have started investing in the infrastructural development of the healthcare sector and promoting treatment services. This can augment the market growth as the awareness among people rises.
Companies have started to combine cancer treatment with machine learning. This will help the specialists identify cancer more efficiently with the CT scans.
The rapid industrialisation in developing countries has propelled the disposable incomes of the population, which can augment the healthcare market and show positive opportunities for the expansion of lung cancer therapeutics.
The development and implementation of nanomedicine can open up new opportunities for the market players and further propel the market development. This method of treatment will target the specific cancer cells for treatment and reduce the adverse effects of therapeutics.
Cancer therapeutics and technologies require skilled and trained professionals for the proper management of the systems.
The devices for cancer therapeutics require extensive amounts of money for maintenance and installation, which can be a hindering factor as smaller health institutions would avoid investing in these technologies.
Inadequate infrastructure and standardisation can hinder cancer care delivery, ultimately hindering the market growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on type, the market can be segmented into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), among others. Based on the therapy, it can be bifurcated into chemotherapy, immunotherapy, radiation therapy, and targeted therapy, among others. Based on end-use, the market segments include hospitals, home care, and speciality clinics, among others. Based on distribution channels, the marker segments include hospital pharmacies, retail pharmacies, and online.
The regional markets for the lung therapeutics market can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.
The extensive E.M.R. report provides an in-depth evaluation of the market based on Porter's five forces model and a SWOT analysis
The lung cancer therapeutics market report comprehensively analyses key players in the market, covering their competitive landscape and the latest developments like mergers, acquisitions, investments, and expansion plans.
Based on type, the market segments include non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Non-small cell lung cancer develops at a slower rate than small-cell lung cancer. The cancer cells in this type are larger compared to the other type. It is the most common type of lung cancer, accounting for a major percentage of lung cancer cases.
Small-cell lung cancer spreads faster than non-small cell lung cancer and there are chances that this type of cancer can come back after treatment. This type of lung cancer is the least common type of lung cancer.
Based on therapies, chemotherapy and radiation therapy hold a significant share of the market as they are the primary type of treatment given to patients. Chemotherapy is a type of cancer treatment conducted by using powerful drugs to kill fast-spreading cells or reduce the symptoms and prolong life.
Radiation therapy involves doses of radiation to kill cancer cells or slow down their growth by damaging their DNA. The treatment focuses on a particular body part where cancer cells are present.
Other treatments include immunotherapy and targeted therapy. Immunotherapy treatment utilises our body’s own immune system’s capabilities to control and treat cancer. It conditions our immune system to identify and attack cancer cells. It strengthens our immune system to fight against cancer cells if they return.
Targeted therapy as a type of cancer treatment utilises drugs to target the specific cells and proteins which help in the growth of cancer.
The lung cancer therapeutics market has several end-users including hospitals, homecare, and speciality clinics, among others. Among these segments, hospitals hold the largest share of the market.
With developing health infrastructure, larger hospitals are equipped with the latest technologies such as Gamma Cameras, PET/CT, CT simulation, and MRI (Magnetic Resonance Imaging), among others, for the diagnosis and treatment of cancer.
Cancer homecare is a specialised care service provided to patients as they deal with a lot of side effects. This service allows the patients to stay in a familiar environment with their families while receiving care from specialist.
Cancer speciality clinics are centres with specialised equipment and trained staff for the treatment of different types of cancer. Many developing countries are developing specialised clinics due to the increasing number of cases.
Based on distribution channels, the market segments include retail pharmacies, hospital pharmacies, and online pharmacies. Among these distribution channels, hospital pharmacy is expected to hold a significant share due to the increasing number of cases in hospitals.
Retail pharmacies are also growing in the market owing to the increasing preference of people to buy medicine from nearby stores. Online pharmacy is expected to hold a higher growth rate due to the rapid growth of the e-commerce industry.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Genentech, Inc. is a biotechnology company based in the United States. They became a part of the Roche Group in March of 2009. They function independently within Roche.
They have been developing medicines for chronic and life-threatening diseases. Some of their major developments were treatment for locally advanced or metastatic non-small lung cancer and pancreatic cancer, and designed antibodies to stop the activation and reactivation of T-cells that cause psoriasis.
AstraZeneca PLC is a multinational company working in the field of pharmaceuticals and biotechnology, with a focus on developing and commercialising prescription medicines. Their areas for medicine development include Oncology, Cardiovascular and Metabolic Disease (CVMD) and Respiratory. They also collaborate with biotech research institutes to work with emerging technologies such as Modified RNA and CRISPR genome editing.
Novartis AG. is a Swiss multinational pharmaceutical company with a focus on creating treatments with science and technology in various sectors such as oncology, ophthalmology, neuroscience, and cardiovascular disorders, among many others. Novartis is also engaged in radioligand therapy, precision imaging, and gyroscope therapeutics.
Merck KGaA is a multinational company for science and technology with operations in different sectors such as healthcare, life science and electronics. They design and develop medicines and smart devices to treat diseases such as cancer and multiple sclerosis.
F. Hoffmann-La Roche Ltd is more commonly known as Roche. It is a multinational healthcare company based in Switzerland. They operate worldwide focusing on two sectors pharmaceuticals and diagnostics. They have started to focus on personalised healthcare with early detection of diseases and accurate diagnosis.
Boehringer Ingelheim International GmbH is a leading biopharmaceutical company, working with professionals on the latest innovation for the diagnosis of diseases for human health. The company works on drug discovery and development, and other healthcare products for heart diseases, metabolic diseases, cancer, lung diseases, mental disorders, and retinal diseases.
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Cancer Type||
|Breakup by Therapy||
|Breakup by Therapy Type||
|Breakup by End User||
|Breakup by Distribution Channel||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Lung Cancer Overview
3.1 Guidelines and Stages
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Lung Cancer Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Lung Cancer Epidemiology (2016-2031)
5.3 Europe Lung Cancer Epidemiology (2016-2031)
5.4 Asia-Pacific Lung Cancer Epidemiology (2016-2031)
5.5 Latin America Lung Cancer Epidemiology (2016-2031)
5.6 Middle East & Africa Lung Cancer Epidemiology (2016-2031)
6 Global Lung Cancer Therapeutics Market Overview
6.1 Global Lung Cancer Therapeutics Market Historical Value (2017-2023)
6.2 Global Lung Cancer Therapeutics Market Forecast Value (2024-2032)
7 Global Lung Cancer Therapeutics Market Landscape
7.1 Global Lung Cancer Therapeutics Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Lung Cancer Therapeutics Product Landscape
7.2.1 Analysis by Cancer Type
7.2.2 Analysis by Therapy
7.2.3 Analysis by End User
8 Lung Cancer Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Lung Cancer Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Lung Cancer Therapeutics Market Segmentation
11.1 Global Lung Cancer Therapeutics Market by Cancer Type
11.1.1 Market Overview
11.1.2 Non-Small Cell Lung Cancer
11.1.3 Small Cell Lung Cancer (SCLC)
11.1.4 Metastatic Lung Cancer
11.2 Global Lung Cancer Therapeutics Market by Therapy
11.2.1 Market Overview
11.2.4 Radiation Therapy
11.2.5 Targeted Therapy
11.3 Global Lung Cancer Therapeutics Market by Therapy Type
11.3.1 Market Overview
11.3.2 Single Drug Therapy
11.3.3 Combination Therapy
11.4 Global Lung Cancer Therapeutics Market by End User
11.4.1 Market Overview
11.4.4 Specialty Clinics
11.5 Global Lung Cancer Therapeutics Market by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospital Pharmacy
11.5.3 Retail Pharmacy
11.5.4 Online Pharmacy
11.6 Global Lung Cancer Therapeutics Market by Region
11.6.1 Market Overview
11.6.2 North America
11.6.4 Asia Pacific
11.6.5 Latin America
11.6.6 Middle East and Africa
12 North America Lung Cancer Therapeutics Market
12.1 Market Share by Country
12.2 United States of America
13 Europe Lung Cancer Therapeutics Market
13.1 Market Share by Country
13.2 United Kingdom
14 Asia Pacific Lung Cancer Therapeutics Market
14.1 Market Share by Country
15 Latin America Lung Cancer Therapeutics Market
15.1 Market Share by Country
16 Middle East and Africa Lung Cancer Therapeutics Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.5 South Africa
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Regulatory Framework
22.1 Regulatory Overview
22.1.1 US FDA
22.1.2 EU EMA
22.1.3 INDIA CDSCO
22.1.4 JAPAN PMDA
23 Supplier Landscape
23.1 Genentech, Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.2 AstraZeneca PLC
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.3 Novartis AG
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.4 Merck KGaA
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.5 F. Hoffmann-La Roche Ltd
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.6 Boehringer Ingelheim International GmbH
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.7 Agennix AG
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.8 Eli Lilly and Company
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.11 Hoffman-La Roche
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
24 Global Lung Cancer Therapeutics Market- Distribution Model (Additional Insight)
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The lung cancer therapeutics market was valued at USD 28.6 billion in 2023.
The market is expected to grow at a CAGR of 11.60% from 2024 to 2032 to reach a value of USD 76.9 billion by 2032.
The lung cancer therapeutics market is driven by the rising development of technology for treatment and diagnosis and an increasing number of cases due to the growth of the smoking population.
Governments are implementing plans to develop their healthcare infrastructure and organisations’ increasing focus on research and development to launch new and innovative treatment solutions are key trends in the market.
The regional markets for the global lung therapeutics market include North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.
There are two main types of cancer available in the market for cancer therapeutics including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), among others.
The market segments for lung cancer therapeutics, based on therapy, include Chemotherapy, Immunotherapy, Radiation Therapy, and Targeted Therapy, among others.
These therapeutics find end-uses in hospitals, home care, and speciality clinics, among others.
The distribution channels in the market for lung cancer therapeutics include hospital pharmacies, retail pharmacies, and online.
If surgery is excluded from the options, combined chemotherapy and radiation therapy is the primary treatment used for lung cancer. For advanced lung cancers, radiation therapy can help in relieving pain and slowing down the advancement of cancer.
The United States Food and Drug Administration has approved Lumakras (sotorasib) for the treatment of non-small cell lung cancer in adult patients whose tumours have a specific genetic mutation known as KRAS G12C.
The key players in the market include Genentech, Inc., AstraZeneca PLC, Novartis AG., Merck KGaA, F. Hoffmann-La Roche Ltd, and Boehringer Ingelheim International GmbH, among others.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.